Regarding “The effect of postoperative myocardial ischemia on long-term survival after vascular surgery”  by Sandoval, Yader & Garcia, Santiago
LETTERS TO THE EDITORRegarding “The effect of postoperative myocardial
ischemia on long-term survival after vascular surgery”
We read with interest the work by The Vascular Study Group
of New England regarding the effect of postoperative myocardial
ischemia on long-term survival after vascular surgery.1 We would
like to make several observations regarding this work.
First, it is remarkable that in this database, the proportion
of patients with a postoperative myocardial infarction (PMI;
1.6%) is higher than the proportion of patients with isolated
cardiac troponin (cTn) elevation (1.3%). Owing to the effects
of anesthesia and other factors, such as widespread use of nar-
cotics for the management of postoperative pain, the vast ma-
jority of perioperative ischemic events are clinically and
electrocardiographically silent.2,3 In the PeriOperative ISchemic
Evaluation (POISE)2 trial, 65% of patients with a PMI did not
experience ischemic symptoms, and for every patient with a
symptomatic MI, there were approximately ﬁve with an isolated
cardiac biomarker elevation (cTn or creatine kinase-MB). Of in-
terest, the risk of death at 30 days was 9.7% in patients with a
symptomatic MI and 12.5% in patients with an asymptomatic
MI.2 Thus, the presence of symptoms in the context of a rise
and fall of cTn may not be as relevant in the postoperative
setting.
Second, the peak cTn value after surgery has been shown to be
prognostically important, in particular if three or more times the
upper reference limit.4 In the study by Simons et al,1 cTn values
are not provided; instead, they are dichotomized as being above
or below a normal upper limit. Such an approach is problematic
because one could erroneously conclude that all patients with an
increased cTn have a very high risk of long-term mortality when,
in reality, only a small number of patients in that group with
very high cTn (eg, three or more) may be responsible for the
poor outcomes of an otherwise low-risk group.
Third, the cTn assays and cutoff decision limits that were used
are not described. We must emphasize that cTn assays are not stan-
dardized, and the characteristics of each assay will affect the ability
to detect ischemia. In addition, how each testing laboratory
deﬁned the upper range limit is unclear, and it must be highlighted
that cTn decision cutoffs, such as the 99th percentile, may not be
uniformly used across laboratories. Future studies should also pro-
vide data on cTn changes (D) because patients may have an
increased cTn with or without the presence of change. These
fundamental aspects are increasingly important, primarily in the
setting of the expected transition to high-sensitivity cTn assays in
the near future.
Finally, it is tempting to think that prophylactic coronary
revascularization before high-risk vascular surgery may be the
best way to prevent perioperative ischemia, but we should
remember the lessons of the Coronary Artery Revascularization
(CARP) trial.5 The most recent Universal Deﬁnition of MI task
force has recognized the importance of PMI and recommended
routine monitoring of cardiac biomarkers in high-risk patients,
before and also 48 to 72 hours after major surgery.6 We believe
the time has come to shift the focus of attention from “preopera-
tive clearance” to perioperative surveillance of myocardial ischemia
with cTns.
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Reply
We appreciate Dr Sandoval’s and Dr Garcia’s interest in our
work. Their comments highlight several aspects of our study that
are important to clarify in order to interpret our ﬁndings. The
observed higher proportion of patients in our study with postop-
erative myocardial infarction than with troponin elevation is
different from the ﬁndings of the PeriOperative ISchemic Evalu-
ation (POISE)1 trial because of key methodologic differences.
Our study was conducted retrospectively, outside of a prospec-
tive clinical trial, and troponin levels were checked only at the
discretion of the provider. In contrast, the POISE trial design
required evaluation of troponin values for all patients. Therefore,
that our study identiﬁed fewer patients with isolated troponin el-
evations is not surprising, and our study likely underestimates
